Ipsen ((GB:0MH6)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: Ipsen is conducting a clinical study titled An Open-Label, Phase I/II First-in-Human, Dose Escalation, Dose Optimisation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 as Single Agent in Adult Participants With Locally Advanced or Metastatic Solid Tumours. The study aims to determine the optimal dosage and assess the safety and effectiveness of IPN60300, a drug intended for adults with advanced solid tumours that have metastasized.
Intervention/Treatment: The intervention being tested is IPN60300, a biological treatment administered via injection. Its purpose is to evaluate its antitumour activity and safety in patients with advanced solid tumours.
Study Design: This interventional study is structured in two phases: Phase Ia involves dose escalation in a single-arm, non-randomized model, while Phase Ib involves dose optimization in a randomized, two-arm parallel model. The primary purpose is treatment, with no masking involved.
Study Timeline: The study is not yet recruiting, with the initial submission on October 1, 2025, and the latest update on October 7, 2025. These dates are crucial as they indicate the study’s current status and progression.
Market Implications: The initiation of this study by Ipsen could influence its stock performance positively, as successful results may lead to a new treatment option for metastatic solid tumours. Investors should monitor this development, considering potential impacts on Ipsen’s market position and comparing it with competitors in the oncology sector.
The study is ongoing, with further details available on the ClinicalTrials portal.